High expression of SULF1 is associated with adverse prognosis in breast cancer brain metastasis

Abstract

Background: Breast cancer is the most common cancer in women, and in advanced stages, it often metastasizes to the brain. However, research on the biological mechanisms of breast cancer brain metastasis and potential therapeutic targets are limited.

Methods: Differential gene expression analysis (DEGs) for the datasets GSE43837 and GSE125989 from the GEO database was performed using online analysis tools such as GEO2R and Sangerbox. Further investigation related to SULF1 was conducted using online databases such as Kaplan–Meier Plotter and cBioPortal. Thus, expression levels, variations, associations with HER2, biological processes, and pathways involving SULF1 could be analyzed using UALCAN, cBioPortal, GEPIA2, and LinkedOmics databases. Moreover, the sensitivity of SULF1 to existing drugs was explored using drug databases such as RNAactDrug and CADSP.

Results: High expression of SULF1 was associated with poor prognosis in advanced breast cancer brain metastasis and was positively correlated with the expression of HER2. In the metastatic breast cancer population, SULF1 ranked top among the 16 DEGs with the highest mutation rate, reaching 11%, primarily due to amplification. KEGG and GSEA analyses revealed that the genes co-expressed with SULF1 were positively enriched in the ‘ECM-receptor interaction’ gene set and negatively enriched in the ‘Ribosome’ gene set. Currently, docetaxel and vinorelbine can act as treatment options if the expression of SULF1 is high.

Conclusions: This study, through bioinformatics analysis, unveiled SULF1 as a potential target for treating breast cancer brain metastasis (BM).

Keywords

brain metastasis / breast cancer / potential therapeutic target / SULF1

References

[1] Zannetti A. Breast cancer: from pathophysiology to novel therapeutic approaches 2.0. Int J Mol Sci. 2023;24(3):2542.

[2] Videira M, Reis RL, Brito MA. Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochim Biophys Acta. 2014;1846(2):312-325.

[3] Mouttet D, Laé M, Caly M, et al. Estrogen-receptor, progesterone-receptor and HER2 status determination in invasive breast cancer. Concordance between Immuno-Histochemistry and MapQuant™ microarray based assay. PLoS One. 2016;11(2):e0146474.

[4] DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer. 1979;44(5):1913-1918.

[5] Breast Cancer Expert Committee of National Cancer Quality Control Center ea. Chinese guidelines for diagnosis and treatment of advanced breast cancer (2022) (in Chinese). Chin J Cancer. 2022;44(12):1262-1287.

[6] Cheng X, Hung MC. Breast cancer brain metastases. Cancer Metastasis Rev. 2007;26(3-4):635-643.

[7] Chien AJ, Rugo HS. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013;137(1):1-12.

[8] Chhichholiya Y, Ruthuparna M, Velagaleti H, Munshi A. Brain metastasis in breast cancer: focus on genes and signaling pathways involved, blood-brain barrier and treatment strategies. Clin Transl Oncol. 2023;25(5):1218-1241.

[9] Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-712.

[10] Shridhar V, Sen A, Chien J, et al. Identification of underexpressed genes in early-and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res. 2002;62(1):262-270.

[11] Mahmoud SA, Mohammed MI, Mahmoud MA, Munkaila A, Yabasin IB. Upregulation of sulfatase-1 decreases metastatic potential of SKOV3 human ovarian cancer cells in vitro and in vivo. J Cancer Res Ther. 2019;15(6):1288-1295.

[12] Lin ZS, Chung CC, Liu YC, et al. EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression. elife. 2023;12:e79432.

[13] Tao Y, Han T, Zhang T, Sun C. Sulfatase-2 promotes the growth and metastasis of colorectal cancer by activating Akt and Erk1/2 pathways. Biomed Pharmacother. 2017;89:1370-1377.

[14] Zhou Q, Jiang Y, Yin W, Wang Y, Lu J. Single-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study. Onco Targets Ther. 2016;9:2749-2757.

[15] Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol. 2016;1418:93-110.

[16] Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956-D963.

[17] Lefebvre C, Bachelot T, Filleron T, et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13(12):e1002201.

[18] Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-1228.

[19] Chinese guidelines for diagnosis and treatment of breast cancer (2022) (In Chinese). Chin J Cancer 2023. 45(10):E006.

[20] Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-751.

[21] Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698-2705.

[22] Hosonaga M, Saya H, Arima Y. Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev. 2020;39(3):711-720.

[23] Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J Neuro-Oncol. 2016;127(3):407-414.

[24] Christodoulou C, Bafaloukos D, Linardou H, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic cooperative oncology group (HeCOG) phase II study. J Neuro-Oncol. 2005;71(1):61-65.

[25] Kouvaris JR, Miliadou A, Kouloulias VE, et al. Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie. 2007;30(7):361-366.

[26] Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neuro-Oncol. 2007;85(2):223-227.

[27] Chargari C, Kirova YM, Diéras V, et al. Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. J Neuro-Oncol. 2009;93(3):379-384.

[28] Alghanim F. Machine learning model for multiomics biomarkers identification for menopause status in breast cancer. Algorithms. 2024;17(1):13.

[29] Zhou L, Rueda M, Alkhateeb A. Classification of breast cancer Nottingham prognostic index using high-dimensional embedding and residual neural network. Cancers (Basel). 2022;14(4):934.

[30] Martin AM, Cagney DN, Catalano PJ, et al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol. 2017;3(8):1069-1077.

[31] Custódio-Santos T, Videira M, Brito MA. Brain metastasization of breast cancer. Biochim Biophys Acta Rev Cancer. 2017;1868(1):132-147.

[32] Gill RM, Mehra V, Milford E, Dhoot GK. Short SULF1/SULF2 splice variants predominate in mammary tumours with a potential to facilitate receptor tyrosine kinase-mediated cell signalling. Histochem Cell Biol. 2016;146(4):431-444.

[33] Rosen SD, Lemjabbar-Alaoui H. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. Expert Opin Ther Targets. 2010;14(9):935-949.

[34] Okolicsanyi RK, Faure M, Jacinto JM, et al. Association of the SNP rs2623047 in the HSPG modification enzyme SULF1 with an Australian Cauian breast cancer cohort. Gene. 2014;547(1):50-54.

[35] Vlodavsky I, Elkin M, Abboud-Jarrous G, et al. Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res. 2008;49(3):207-210.

[36] Muschler J, Streuli CH. Cell-matrix interactions in mammary gland development and breast cancer. Cold Spring Harb Perspect Biol. 2010;2(10):a003202.

[37] Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891-906.

[38] Tang Y, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005;65(8):3193-3199.

[39] de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374-403.

RIGHTS & PERMISSIONS

2024 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.